E
PSTX

Ergoteles’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Ergoteles’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,600
Closed -$100K – 1627
2023
Q1 		$100K Buy
+32,600
New +$195K ﹤0.01% 1102
2022
Q4 		– Sell
-93,842
Closed -$331K – 1983
2022
Q3 		$331K Sell
93,842
-42,478
-31% -$140K 0.01% 935
2022
Q2 		$352K Buy
+136,320
New +$379K 0.01% 1024
2021
Q3 		– Sell
-28,300
Closed -$284K – 1771
2021
Q2 		$284K Buy
+28,300
New +$253K 0.01% 1100

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Ergoteles's PSTX Position: Q2 2023 in Review

Ergoteles sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 32,600 shares — an estimated $100K sold.

Ergoteles first reported a position in PSTX in Q2 2021 and held it in 4 quarters. The position peaked at $352K in Q2 2022. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Ergoteles reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 32,600 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $100K.
  • Ergoteles first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Ergoteles's Poseida Therapeutics, Inc. Common Stock position peaked at $352K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.